Landmark Bio
Landmark Bio is an advanced therapy CDMO providing process development, cGMP manufacturing, fill & finish, and CMC regulatory services across viral vectors, cell therapies, nucleic acids, extracellular vesicles, and lipid nanoparticles, serving academic researchers and biopharma clients from its Watertown, MA facility.
- Company typePrivate
- Founded2020
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Landmark Bio does
Landmark Bio is an advanced therapy contract development and manufacturing organization (CDMO) headquartered in Watertown, Massachusetts, operating from a 44,000-square-foot integrated facility housing ISO 7 and ISO 8 GMP processing suites, five cell processing suites, two viral vector suites, an mRNA/LNP suite, and a fill & finish suite. The company was founded in 2020 by a consortium that included Harvard, MIT, Cytiva, FUJIFILM Diosynth Biotechnologies, Alexandria Real Estate Equities, and four Boston-area research hospitals (Boston Children's, Dana-Farber, Mass General Brigham, Beth Israel Deaconess). The facility opened in mid-2022, and in 2025 Landmark Bio was acquired by Artis BioSolutions as a wholly-owned entity.
Landmark Bio firmographics
Firmographics- Name
- Landmark Bio
- Legal name
- Landmark Bio LLC
- Website
- https://landmarkbio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Landmark Bio is an advanced therapy CDMO providing process development, cGMP manufacturing, fill & finish, and CMC regulatory services across viral vectors, cell therapies, nucleic acids, extracellular vesicles, and lipid nanoparticles, serving academic researchers and biopharma clients from its Watertown, MA facility.
- Ownership category
- akta.pro rank
Landmark Bio industry classification
Industry- Product category
- Cell and Gene Therapy Contract Manufacturing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
Keywords
Where Landmark Bio is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Landmark Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Landmark Bio operates as a CDMO providing fee-for-service contract manufacturing and development services to biotech and pharma companies. Revenue is generated through project-based contracts for process development, analytical development, cGMP manufacturing, fill & finish, and regulatory consulting services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Landmark Bio product offering
Product offeringCore offering
Landmark Bio is an advanced therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning process and analytical development, formulation development, cGMP cell and gene therapy manufacturing, fill and finish, quality control testing, CMC regulatory consulting, and IND-enabling services. The company supports modalities including viral vectors (LVV, AAV), cell therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), nucleic acids, extracellular vesicles, and lipid nanoparticles for biotech, pharma, and academic clients from bench to clinic.
Product overview
Landmark Bio is an advanced therapy CDMO organized as a platform of interconnected services with modular delivery options. The core offering consists of eight integrated service lines—Process & Analytical Development, Formulation Development, Cell & Gene Therapy Manufacturing, Fill & Finish, Quality Control Testing, CMC Regulatory & Drug Development Consulting, IND-Enabling Services, and Technology Development—that collectively span the full bench-to-clinic journey. These services support five therapeutic modalities: Viral Vectors (LVV, AAV, novel viruses), Cell Therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), Nucleic Acids, Extracellular Vesicles, and Nanoparticles/Non-viral Delivery. The portfolio is anchored by three POSTmarkTM platforms (LVV, AAV, CAR-T) that provide pre-established, scalable manufacturing processes for rapid cGMP adoption. Three flexible partnership models—On-Demand Platforms, Modular Service Offerings, and Joint Innovation—determine how clients engage with these services.
Differentiator
Problem solved
Functional benefit
Products and services
- Process & Analytical Development Comprehensive upstream, downstream, cell therapy, viral vector, and non-viral delivery process development plus analytical development services including phase-appropriate method development, qualification, and verification for advanced therapy manufacturers.
- Formulation Development Formulation services for nanomedicines and cell therapies/viral vectors, including rational design of nanoparticle formulations, buffer/excipient composition, cryopreservation parameters, and stability studies.
- Cell & Gene Therapy Manufacturing cGMP manufacturing services for advanced therapies including CAR-T, CAR-NK, iPSC, MSC, HSC, lentiviral vectors, AAV, retroviruses, lipid nanoparticles, and extracellular vesicles, performed in purpose-built modular ISO 7 and ISO 8 processing suites.
- Fill & Finish Aseptic fill and finish processing using Crystal M1 filling station and Cytiva Microcell robotic isolator for pharmaceutical vial filling of advanced therapy drug products.
- Quality Control Testing Comprehensive QC testing services including DNA/RNA quantitation (ddPCR, qPCR), automated cell counters, flow cytometry, HPLC, sterility and endotoxin testing, and full release testing for cell and gene therapies.
- CMC Regulatory & Drug Development Consulting Regulatory and CMC consulting services including target product profiles, process and product characterization, critical process parameters, regulatory risk assessment, CTD Module 3 preparation, and health authority interactions.
- IND-Enabling Services Bespoke CMC work packages to accelerate programs into the clinic, including non-GMP material supply, process development, analytical development, GMP material supply, and regulatory support for IND submission and approval.
- Technology Development Technology development services leveraging academic and industry partnerships to translate groundbreaking research into advanced therapies, including product prototyping, optimization, and novel modality development.
- Viral Vectors Modality Services Manufacturing and development services for lentiviral vectors (LVV), adeno-associated virus (AAV), and novel viral vectors for gene therapy applications.
- Cell Therapies Modality Services Development and cGMP manufacturing services for CAR-T, CAR-NK, iPSC, MSC, HSC, and novel cell therapies for oncology, regenerative medicine, autoimmune disease, and rare disease applications.
- Nucleic Acids Modality Services Services for nucleic acid-based therapeutics including rational particle design and formulation, process and analytical development, and GMP manufacturing for diverse nucleic acid compositions.
- Extracellular Vesicles (EVs) Modality Services Optimization and manufacturing services for extracellular vesicle therapies, including cell line engineering, cargo loading, scalable production (fed batch and continuous perfusion), downstream purification, and lot release testing.
- Nanoparticles & Non-viral Delivery Modality Services Development and manufacturing services for nanoparticle-based therapies including lipid nanoparticles (LNPs), inorganic nanoparticles, formulation development, and physio-chemical characterization.
- Flexible Partnership Models Three engagement models offered to clients: On-Demand Platforms leveraging validated production platforms, Modular Service Offerings for process transfer to GMP facility, and Joint Innovation packages spanning preclinical through commercialization.
Companies that use Landmark Bio
Customer profileSegments2 records
Ideal customer profiles2 records
Landmark Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Landmark Bio partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and major.
- Harvard UniversitycoreHarvard, along with MIT, was an academic founding partner of Landmark Bio. The partnership provides access to groundbreaking research and enables translation of academic discoveries into clinical therapies. Harvard Stem Cell Institute and Harvard Medical School contribute scientific expertise through the Science & Technology Advisory Committee.
- Massachusetts Institute of Technology (MIT)coreMIT, along with Harvard, was an academic founding partner of Landmark Bio. MIT Center for Biomedical Innovation (CBI) provides scientific leadership including Executive Director Stacy Springs who chairs Landmark Bio's Science and Technology Committee.
- CytivacoreCytiva was an industrial founding partner of Landmark Bio, providing state-of-the-art technologies and capabilities. Chief Technology Officer Beate Mueller-Tiemann serves on the Science and Technology Advisory Committee.
- FUJIFILM Diosynth BiotechnologiescoreFUJIFILM Diosynth Biotechnologies was an industrial founding partner of Landmark Bio. Chief Science Officer Andy Topping serves on the Science and Technology Advisory Committee, contributing expertise in contract development and manufacturing of biologics.
- Boston Children's HospitalcoreBoston Children's Hospital was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
- Dana-Farber Cancer InstitutecoreDana-Farber Cancer Institute was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
- Mass General BrighamcoreMass General Brigham was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
- Beth Israel Deaconess Medical CentercoreBeth Israel Deaconess Medical Center was among Boston's leading hospitals that formed the founding consortium to accelerate life sciences innovations.
- NIIMBLmajorNIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals) is a U.S. public-private partnership focused on biopharmaceutical manufacturing innovation. Landmark Bio participates in consortium projects including work with MIT, EMD Millipore, and Virica Biotech to reduce empty viral capsids in AAV production. Landmark Bio also received NIIMBL grants with ChromaTan for intensified AAV production.
- ChromaTan Inc.majorLandmark Bio and ChromaTan were awarded a NIIMBL grant to develop a scalable and cost-effective process for manufacturing AAV-based gene therapy vectors, leveraging advanced technologies to improve purification efficiency and reduce costs.
- EverGlade ConsultingmajorEverGlade Consulting supported Landmark Bio in securing up to $18.3 million in ARPA-H funding through the TRANSFORM-EV program. EverGlade guided Landmark Bio through the federal funding process, including negotiations, project structuring, and financial planning for the three-year extracellular vesicle manufacturing platform project.
- Artis BioSolutionscoreArtis BioSolutions, a San Diego-based advanced-therapies development and manufacturing company, acquired Landmark Bio in 2025 as a wholly-owned entity. The acquisition integrates Landmark Bio's U.S. platform with Artis' existing capabilities, creating a combined offering for advanced-therapy developers globally.
Scale indicators6 records
Recent moves9 records
Expansion highlights2 records
Landmark Bio competitors and assessment
Company assessmentEmerging players
- Resilience: Technology-focused biopharmaceutical CDMO building capacity across biologics, viral vectors, and cell therapies. An emerging scaled competitor with overlapping modalities to Landmark Bio's portfolio.
- Vineti: Specialized cell and gene therapy orchestration platform providing chain-of-custody, manufacturing workflow, and logistics software. Comparable as an emerging ecosystem enabler for cell therapy commercialization adjacent to Landmark Bio's manufacturing services.
Broad incumbents
- Thermo Fisher Scientific: Operates one of the world's largest CDMO networks (Patheon) including viral vector and cell therapy services. A scaled incumbent competing for advanced therapy contracts with broader portfolio reach than Landmark Bio.
- Samsung Biologics: Large-scale contract manufacturer expanding into advanced therapies and gene therapy. Serves similar biopharma customers with broader capacity but less specialization in autologous cell therapies.
Direct peers
- AGC Biologics: Global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services with GMP facilities across multiple geographies. Closely comparable mid-to-large advanced therapy CDMO competitor.
- Aldevron: Specializes in plasmid DNA, mRNA, and viral vector manufacturing for gene and cell therapies (now part of Danaher). Directly competes with Landmark Bio in viral vector and nucleic acid CDMO services.
- Lonza: Global leader in cell and gene therapy CDMO services, offering process development, GMP manufacturing, and fill & finish across viral vectors, cell therapies, and biologics. Direct competitor to Landmark Bio across nearly every modality it serves.
- FUJIFILM Diosynth Biotechnologies: Large-scale CDMO with deep viral vector, gene therapy, and biologics manufacturing capabilities. Both a founding industrial partner and a direct competitor to Landmark Bio in the CDMO market.
- Catalent: Major CDMO with significant advanced therapy capabilities in cell therapy, viral vectors, and biologics manufacturing (now owned by Novo Holdings). Competes head-to-head with Landmark Bio for biotech and biopharma development and manufacturing contracts.
- Charles River Laboratories: Provides CDMO services including cell and gene therapy manufacturing, viral vector production, and biologics testing. Overlaps directly with Landmark Bio's process development, GMP manufacturing, and QC offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Landmark Bio social profiles
Digital presenceLandmark Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Landmark Bio leadership team
Management profileNumber of profiles
Profiles6 records
Landmark Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Landmark Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Landmark Bio
What does Landmark Bio do?
Landmark Bio is an advanced therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services spanning process and analytical development, formulation development, cGMP cell and gene therapy manufacturing, fill and finish, quality control testing, CMC regulatory consulting, and IND-enabling services. The company supports modalities including viral vectors (LVV, AAV), cell therapies (CAR-T, CAR-NK, iPSC, MSC, HSC), nucleic acids, extracellular vesicles, and lipid nanoparticles for biotech, pharma, and academic clients from bench to clinic.
Is Landmark Bio a public or private company?
Landmark Bio is a private company. It is classified as corporate owned and is currently operating.
When was Landmark Bio founded?
Landmark Bio was founded in 2020. It employs 51 to 100 people.
Where is Landmark Bio based?
Landmark Bio is headquartered in Boston, United States, in the North America region.
How does Landmark Bio make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Landmark Bio's main competitors?
Emerging players on record are Resilience and Vineti. Broad incumbents are Thermo Fisher Scientific and Samsung Biologics. Direct peers are AGC Biologics, Aldevron, Lonza, FUJIFILM Diosynth Biotechnologies, Catalent and Charles River Laboratories.
Does Landmark Bio have an API?
No public API is recorded for Landmark Bio.
What industry is Landmark Bio in?
Landmark Bio's product category is Cell and Gene Therapy Contract Manufacturing. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.